Orbimed Advisors LLC Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Orbimed Advisors LLC increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 137.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,059,971 shares of the biopharmaceutical company’s stock after purchasing an additional 612,771 shares during the quarter. Xenon Pharmaceuticals makes up 1.1% of Orbimed Advisors LLC’s holdings, making the stock its 22nd biggest position. Orbimed Advisors LLC’s holdings in Xenon Pharmaceuticals were worth $61,637,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of XENE. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the third quarter worth $32,000. Blue Trust Inc. increased its position in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at $33,000. Osaic Holdings Inc. raised its stake in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $43,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Shares of XENE opened at $65.42 on Monday. The firm has a market capitalization of $6.32 billion, a P/E ratio of -13.92 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a 12-month low of $30.00 and a 12-month high of $72.66. The firm has a fifty day moving average price of $58.30 and a 200-day moving average price of $52.69.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the previous year, the company posted ($0.83) earnings per share. Analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on XENE. Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada boosted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $77.20.

Insider Activity

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.91% of the stock is owned by insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.